USA – Dren Bio, a Foster City, CA-based clinical-stage biopharmaceutical company, raised $65M in Series B funding.
The round was led by Aisling Capital and HBM Healthcare Investments, with participation from Pfizer, ArrowMark Partners, Revelation Partners, SR One, 8VC, Taiho Ventures, BVF Partners, Mission BioCapital and Alexandria Venture Investments, amongst others. In connection with the closing of the financing, Andrew Schiff, M.D., of Aisling Capital, and Chandra P. Leo, M.D., of HBM Partners, will join its Board of Directors.Proceeds from the financing will enable the company to continue advancement of its broad internal pipeline comprised of multiple development candidates approaching the clinic. Led by CEO Nenad Tomasevic, Dren Bio is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseases. Its pipeline encompasses two distinct programs, the first focusing on the engineering of antibodies with enhanced antibody-dependent cellular cytotoxicity (“ADCC”) capabilities and the second revolving around its proprietary Targeted Myeloid Engager and Phagocytosis Platform. Its lead asset, DR-01, is designed to precisely eliminate a subset of immune cells which are the underlying cause of certain hematologic malignancies and well-defined autoimmune disorders, both of which will be evaluated using its current funding.14/06/2022
